These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey.
    Author: Bavbek S, Mungan D, Türktaş H, Mısırlıgil Z, Gemicioğlu B, ADVISE Study Group.
    Journal: Respir Med; 2011 Apr; 105(4):541-8. PubMed ID: 21035319.
    Abstract:
    OBJECTIVE: To calculate direct cost per asthma exacerbation at tertiary healthcare centers across Turkey. METHODS: A total of 294 persistent asthma patients (mean age: 50.4±15.1 years) were included in this retrospective study upon admission with an acute asthma attack. Direct costs including drug treatment, non-drug treatment, healthcare resource utilization, emergency care, tests and consultations were calculated per asthma attack in relation to asthma attack severity. RESULTS: The asthma attack was moderate in 57.5% of the patients. Direct cost was €214.9 (95% CI: 183.9; 245.8) per attack. The cost of severe attack €308.2 (95% CI: 258.2; 358.2)] was significantly higher than moderate [€172.6 (95% CI: 155.1; 190.2)] and mild [€128.6 (95% CI: 102.6; 154.7) attacks. It was also significantly higher for inpatient follow-up [€257.7 (95% CI: 220.4; 295)] vs. outpatient follow-up [€54.5 (95% CI: 47; 62; p<0.001)] and uncontrolled asthma [€288.2 (95% CI: 216.7; 359.6)] vs. controlled [€128.9 (95% CI: 92.1; 165.8); p<0.01] asthma. CONCLUSION: Health policies targeting achievement of better asthma control and lower disease severity during the stable periods of the disease as well as appropriate hospitalization of patients and rational prescribing of drugs will play crucial role in the reduction of economic burden of asthma for the patient and the society.
    [Abstract] [Full Text] [Related] [New Search]